FDA approves Kerendia for the therapy of CKD, kind 2 diabetes

0
466

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved Kerendia for reducing the risk of kidney and heart complications in adults with chronic kidney disease related to type 2 diabetes.

In a randomized, multicenter, double-blind study, researchers compared the effectiveness of Kerendia (Finerenone) tablets with placebo in 5,674 patients with CKD. According to study results, 504 patients out of 2,833 patients who received Kerendia had a composite endpoint of either a 40% reduction in kidney function, progression to kidney failure, or kidney death versus 600 patients out of 2,841 who received placebo. In addition, 367 patients who received Kerendia compared to 420 patients who received placebo experienced cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization.

FDA approval
Source: Adobe Stock

Kerendia received a priority review as well as a quick assignment.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio